Publications (60) Antonio Manuel Lax Perez publications

filter_list

2025

  1. AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury

    Molecular Medicine, Vol. 31, Núm. 1

  2. Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings

    Frontiers in Pharmacology

  3. miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation

    International Journal of Molecular Sciences, Vol. 26, Núm. 20

2024

  1. Circulating concentrations and prognostic value of incretin hormones GLP-1 and GIP-1 in patients with heart failure.

    ESC Congress - Heart Failure 2024

  2. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis

    ESC Congress 2024

2023

  1. Circulating ST2, from biomarker to pathogenic mediator

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 672-674

  2. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 704-720

2022

  1. Critical warm ischemia time point for cardiac donation after circulatory death

    American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328

  2. Editorial: Myocardial Remodeling: Mechanisms and Translational Implications

    Frontiers in Pharmacology

2021

  1. The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status (Scientific Reports, (2020), 10, 1, (13553), 10.1038/s41598-020-70454-8)

    Scientific Reports

  2. Differences in the Interleukin-1β/Soluble ST2 Interplay Between Acute and Chronic Heart Failure

    Journal of Cardiovascular Translational Research

  3. Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Reply: Interleukin-1β and sST2

    Journal of the American College of Cardiology

  2. Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction

    Diabetes and Metabolism

  3. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure

    Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1016-1025

  4. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

    JACC: Basic to Translational Science, Vol. 4, Núm. 7, pp. 831-840

  5. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction

    Journal of Molecular and Cellular Cardiology, Vol. 130, pp. 216-233

2018

  1. Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)

    American Journal of Cardiology, Vol. 122, Núm. 4, pp. 578-583

  2. Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction

    Journal of the American College of Cardiology